Pancreatic ductal adenocarcinoma (PDAC) has proven resistant to immunotherapies that succeeded against other cancers. New research published in Cell reveals a promising combination strategy: pairing KRAS inhibitors with 21h10, a synthetic mimic of the immune cytokine IL-21. In mouse models, this combination produced durable tumor remissions by activating CD4 T cells—contrary to conventional approaches focusing on CD8 T cells—which recruited macrophages to eliminate tumors. The KRAS inhibitor creates a therapeutic window by shrinking tumors and reducing immunosuppressive signals, allowing 21h10 to drive potent anti-tumor responses. Remarkably, complete tumor clearance occurred without requiring CD8 T cells or MHC class I expression on tumor cells. Instead, 21h10 expanded Th1-polarized CD4 T cells that produced interferon-gamma. Critically, T cells from human pancreatic tumors demonstrated responsiveness to 21h10 in laboratory experiments, suggesting this mechanism may translate to patients. This research challenges existing immunotherapy paradigms and offers a novel approach to extend KRAS inhibitor benefits in pancreatic cancer, a historically difficult-to-treat malignancy.

AstraZeneca's ETCAMAH (camizestrant) has received FDA accelerated approval in combination with CDK4/6 inhibitors (abemaciclib, palbociclib, or ribociclib) for treating hormone receptor-positive, HER2-negative advanced or metastatic breast cancer with emergent ESR1 mutations detected during aromatase inhibitor and CDK4/6 inhibitor therapy. The approval follows results from the pivotal SERENA-6 Phase III trial, presented at the 2025 American Society of Clinical Oncology Annual Meeting and published in The New England Journal of Medicine. The trial demonstrated that the combination reduced disease progression or death risk by 56 percent compared to standard aromatase inhibitor therapy with CDK4/6 inhibitors, with a hazard ratio of 0.44 and median progression-free survival of 16.0 versus 9.2 months. This approval represents AstraZeneca's tenth FDA authorization this year and fourth in breast cancer, marking the first first-line medicine of its type utilizing circulating tumor DNA detection. The combination addresses approximately one-third of advanced breast cancer patients developing ESR1 mutations, enabling earlier therapeutic intervention before clinical progression and potentially improving patient outcomes and quality of life.

In vivo CAR-T cell therapy represents a transformative approach in oncology and autoimmune disease treatment, directly engineering T cells within patients' bodies rather than ex vivo. This method leverages advanced delivery technologies including lipid nanoparticles and lentiviral vectors to reduce manufacturing costs, accelerate timelines, and enhance therapeutic accessibility. However, the complexity of integrating targeted delivery, gene expression, immune response, and safety assessment demands rigorous preclinical validation. WuXi Biology has developed a comprehensive integrated framework addressing these challenges, establishing a standardized workflow from molecular design through in vivo validation. The framework encompasses three synergistic core modules: the first utilizes mature antibody discovery platforms—phage display, hybridoma technology, and single B-cell analysis—to identify and characterize high-affinity, high-specificity binders and CAR extracellular antigen-binding domains. Additionally, high-throughput CAR functional screening systems, including Jurkat reporter assays, evaluate CAR-mediated functionality. This end-to-end continuity enhances preclinical research efficiency and data interpretability, effectively supporting progression toward Investigational New Drug applications and advancing in vivo CAR-T product development.

Antimicrobial resistance (AMR) represents an escalating threat to modern medicine, as bacteria evolve to resist existing antibiotics, compromising everything from routine surgeries to cancer treatment and organ transplantation. The World Health Organization identifies AMR as a critical global health crisis, with resistant infections linked to approximately 4.95 million deaths worldwide in 2019, including 1.27 million deaths directly attributable to resistance. Unchecked AMR could reduce global GDP by 3.8 percent by 2050 and push 28 million people into poverty according to World Bank projections. In response, stakeholders across healthcare, biotechnology, regulation, and investment sectors are increasingly exploring alternative treatment strategies. Phage therapy, which uses naturally occurring viruses called bacteriophages to target harmful bacteria, has emerged as a promising area attracting renewed scientific and commercial attention. This approach sits at the intersection of healthcare innovation, biotechnology investment, regulatory strategy, and life sciences risk management, offering potential solutions to combat difficult-to-treat infections as conventional antibiotics lose efficacy.

Lipids are fundamental components of the brain, crucial for synaptic transmission and signal propagation. Altered brain lipid composition is associated with common and rare neuropathologies, yet the spatial organization of the mammalian brain lipidome remains insufficiently characterized compared with other modalities. Here we mapped the membrane-lipid architecture of the adult mouse brain at micrometric scale, across sexes and during pregnancy. This lipid brain atlas reveals that lipids describe a fine-grained biochemical structure that aligns with functional anatomy. Membrane-lipid spatial heterogeneity clusters into territories, which we termed ‘lipizones’. Lipizones partially mirror cell-type territories, but also capture distal axon terminals.

This review examines the latest advances in in vivo CAR-T cell therapy, a promising immunological approach for treating cancer and other diseases. Rather than engineering T cells outside the body, in vivo CAR-T therapy generates chimeric antigen receptor-expressing cells directly within patients, potentially improving treatment accessibility and reducing manufacturing complexity. The article surveys recent progress in this field, detailing emerging techniques and methodologies that enhance CAR-T cell generation and function in living organisms. Key developments include innovations in genetic engineering approaches, optimized delivery mechanisms, and strategies to overcome immunological barriers. The review highlights clinical and preclinical findings demonstrating improved efficacy and safety profiles compared to traditional ex vivo approaches. In vivo CAR-T therapy matters significantly because it addresses critical limitations of conventional CAR-T treatments, including high costs, extended production timelines, and manufacturing standardization challenges. By enabling direct cellular reprogramming within patients, this approach could democratize access to advanced cancer immunotherapies and expand treatment possibilities for diverse patient populations and disease indications.

# Professional Summary This article published in the Cureus Journal of Medical Science addresses innovative therapeutic approaches beyond traditional antibiotic treatments. The research, authored by Benny Vijayanandh Avanigadda, Raja Krishna Venigalla, Renusri Ede, Pranathi Reddy Jetti, Venkataramana Kandi, and Tarun Kumar Suvvari, explores alternative strategies to combat antimicrobial resistance and infectious diseases. The article likely examines emerging technologies and methodologies such as bacteriophage therapy, antimicrobial peptides, immunotherapy, or targeted drug delivery systems that offer potential solutions to antibiotic-resistant pathogens. Given the escalating global health threat posed by antimicrobial resistance, this comprehensive review is significant for medical professionals, pharmaceutical researchers, and healthcare policymakers seeking evidence-based alternatives to conventional antibiotics. The findings contribute to the growing body of literature supporting the development and clinical implementation of next-generation therapeutic options that can complement or replace traditional antibiotic regimens in various clinical scenarios.

Amgen announced landmark results from the Phase 3 DeLLphi-305 study demonstrating that IMDELLTRA (tarlatamab-dlle), a bispecific T-cell engager therapy, in combination with AstraZeneca's Imfinzi (durvalumab) significantly improved overall survival compared to durvalumab alone in patients with extensive stage small cell lung cancer. The study evaluated IMDELLTRA as first-line maintenance treatment for ES-SCLC patients whose disease had not progressed following initial treatment with durvalumab, platinum-based chemotherapy, and etoposide. Beyond the primary endpoint, the combination also achieved statistically significant improvements in progression-free survival and objective response rate. The safety profile remained consistent with known profiles of individual medicines, with no new safety signals identified. This represents the first Phase 3 study of a BiTE therapy to demonstrate overall survival benefit in the first-line maintenance setting for ES-SCLC. Given that extensive stage small cell lung cancer remains one of the most aggressive cancers with rare substantial survival improvements, these results potentially shift the treatment paradigm and establish a new standard of care earlier in the disease journey for affected patients.

Breast cancer represents the most common malignancy among women worldwide, with hormone receptor-positive, HER2-low disease presenting particular clinical challenges once resistance develops to standard endocrine therapy and CDK4/6 inhibitors. This case report from Shenzhen Hospital, Southern Medical University, documents a 45-year-old female patient with HR+/HER2-low metastatic breast cancer who had progressed on conventional treatments. The patient received a combination of trastuzumab deruxtecan, a HER2-directed antibody-drug conjugate, paired with fulvestrant, a selective estrogen receptor degrader. The treatment demonstrated significant clinical efficacy and favorable tolerability, achieving a progression-free survival of 26 months without any grade 3 or higher adverse events. HER2-low breast cancer, defined as HER2 1+ or 2+ expression with negative in situ hybridization results, represents approximately 60% of HER2-negative cases and has emerged as an important therapeutic target. The authors suggest this combination approach may constitute a promising strategy for patients with advanced, treatment-refractory HR+/HER2-low breast cancer, potentially offering clinicians a valuable option for managing this previously difficult-to-treat patient population.

# Summary This Nature article, authored by Boston Consulting Group healthcare experts, examines the evolving landscape of in vivo CAR T cell therapies. In vivo CAR T approaches represent a significant advancement in cancer immunotherapy, enabling T cells to be engineered within the patient's body rather than through traditional ex vivo manufacturing. The analysis, supported by contributions from H. Zhang and Z. Chowdhury, provides insights into both preclinical and clinical developments in this therapeutic domain. The piece is particularly valuable for biopharmaceutical stakeholders seeking to understand how in vivo CAR T strategies are reshaping treatment paradigms. By contrasting in vivo approaches with conventional ex vivo CAR T manufacturing, the article highlights potential advantages including reduced manufacturing complexity, lower costs, and improved accessibility. This comprehensive review matters because in vivo CAR T therapies could democratize advanced cellular immunotherapy, extending effective cancer treatments to broader patient populations while addressing supply chain limitations that currently constrain ex vivo CAR T deployment.

Traditional screening-based drug discovery is inherently limited by the astronomical scale of the chemical space. Generative modelling offers a compelling alternative to the classical search paradigm and enables rational, bottom-up design of novel and target-specific small molecules. However, its impact has been hampered by challenges in synthetic accessibility of the designed compounds and lack of large-scale experimental validation. Here, we introduce LDDM (Large Drug Discovery Model), a generative framework that supports a range of drug discovery tasks, including constrained and unconstrained docking, fragment linking and growing, and de novo design. We further introduce a programmable design algorithm that enables accurate design of synthetically accessible compounds satisfying various fine-grained objectives.

Researchers from University College London, Oxford, and Leicester have developed a flow-enabled 3D micro-bladder model to better understand recurrent urinary tract infections and evaluate phage therapy effectiveness. This novel platform integrates a fluidic system that mimics urine flow dynamics, providing a more physiologically relevant testing environment than traditional static lab cultures. The study revealed that uropathogenic Escherichia coli, responsible for most UTIs, demonstrates significantly higher infectivity in the flow-augmented model, with bacteria infiltrating the bladder lining and forming persistent reservoirs that likely explain frequent UTI recurrence. When tested in this advanced model, nitrofurantoin, a first-line antibiotic, proved less effective than in standard susceptibility tests, highlighting why current treatments often fail in patients. The research addresses a critical clinical problem: antibiotics frequently fail to completely eliminate UTI infections due to growing antimicrobial resistance. By demonstrating that bacteriophage therapy shows promise in this more realistic tissue model, this work offers a potential alternative treatment strategy for recurrent UTIs and underscores the importance of physiologically accurate testing systems for translating laboratory findings into effective clinical therapies.

In the phase 1b/2 BEGONIA platform trial, the combination of trastuzumab deruxtecan and durvalumab demonstrated remarkable efficacy as a first-line treatment for hormone-receptor-negative, HER2-low metastatic breast cancer. Trastuzumab deruxtecan, developed by Daiichi Sankyo and AstraZeneca, is an antibody-drug conjugate that delivers potent chemotherapy directly to HER2-expressing cells, while durvalumab blocks PD-L1 to enhance immune activation. The combination achieved tumor shrinkage in approximately sixty percent of patients, with many maintaining responses at analysis completion—an unusually durable pattern for this aggressive disease. Hormone-receptor-negative breast cancer, predominantly triple-negative, ranks among the most lethal breast cancer subtypes, affecting younger women disproportionately and progressing rapidly to distant organs. Traditional treatment relies on cytotoxic chemotherapy with platinum salts and taxanes, with limited immunotherapy benefit restricted to PD-L1 high-expressing tumors. The BEGONIA findings, published in Nature Cancer, represent the most mature clinical evidence yet for combining HER2-targeted therapy with immunotherapy in this population, potentially transforming treatment paradigms for patients previously limited to nonselective chemotherapy approaches.

Cancer immunotherapies, including adoptive T-cell therapies and checkpoint inhibitors, have revolutionized treatment for many malignancies, yet only a subset of patients achieve durable responses. The tumor metabolic microenvironment significantly contributes to this therapeutic gap. Tumor cells compete with infiltrating lymphocytes for essential nutrients like glucose and glutamine while accumulating immunosuppressive metabolites including lactate, adenosine, and kynurenine. This metabolic stress drives T-cell mitochondrial dysfunction and exhaustion, compromising treatment efficacy. Metabolomics has emerged as a critical analytical tool bridging these observations with interventions. Advanced techniques including mass spectrometry, spatial metabolic imaging, stable-isotope flux analysis, and single-cell profiling now enable detailed mapping of metabolite gradients and identification of treatment-response biomarkers. Parallel efforts focus on metabolic reprogramming of CAR-T and TCR-T therapies, dietary interventions, and targeting metabolic checkpoints to enhance T-cell function. However, significant challenges remain: metabolomic findings are often correlative rather than causal, spatial resolution within tumors is limited, and translation from preclinical models to patients remains inconsistent. This research initiative seeks mechanistic, translational, and clinical studies advancing causal understanding of cancer metabolomics in T-cell immunotherapy, ultimately improving patient outcomes through validated metabolic biomarkers and novel therapeutic strategies.

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized blood cancer treatment with seven FDA-approved options, yet conventional manufacturing remains time-consuming, expensive, and produces variable outcomes. Nyberg and colleagues published a groundbreaking study in Nature (2026) proposing an innovative in vivo approach to circumvent these manufacturing bottlenecks. Rather than extracting and engineering T cells outside the body, their two-vector system delivers CRISPR-Cas9 machinery directly to patients to generate CAR T cells within the body itself. The strategy specifically targets the T-cell receptor alpha constant (TRAC) locus, a T-cell-specific genomic site enabling sustained, physiological CAR expression while minimizing off-target integration risks. The researchers employed optimized adeno-associated viruses (AAVs) and enveloped delivery vehicles (EDVs), including a novel AAV-hT7 capsid with enhanced performance in human serum and T-cell targeting. In humanized mouse models, this approach successfully generated therapeutic CAR T-cell levels and controlled tumor growth. This advancement addresses critical clinical challenges by potentially accelerating treatment timelines, reducing manufacturing complexity and costs, and improving product consistency, thereby democratizing access to CAR T therapy.

Merck and Moderna announced positive Phase 3 results for intismeran autogene, a personalized mRNA cancer vaccine, marking a watershed moment for oncology immunotherapy. The INTerpath-001 trial enrolled 1,137 patients with surgically resected high-risk melanoma (stages IIB-IV) and demonstrated that intismeran combined with Merck's checkpoint inhibitor pembrolizumab (Keytruda) achieved statistically significant improvements in both recurrence-free survival and distant metastasis-free survival compared to pembrolizumab monotherapy. Critically, this represents the first positive Phase 3 readout for any individualized neoantigen mRNA cancer therapy. No new safety signals emerged, with tolerability consistent with previous reports. Unlike conventional treatments, intismeran is personalized; each dose is tailored to the individual patient's tumor mutations. Study principal investigator Georgina Long emphasized the potential to establish a new treatment paradigm in adjuvant melanoma care, while Yale dermatologist Christopher Bunick called it "one of the most monumental advancements" in dermatology. This milestone validates mRNA's transition from experimental promise to clinical proof in cancer treatment, pending regulatory approval.

In a paper published recently in the Proceedings of the National Academy of Sciences (PNAS), a team led by Eugene Shakhnovich, Roy G. Gordon Professor of Chemistry, and Vaibhav Mohanty, an M.D./Ph.D. student at the Harvard Kenneth C. Griffin Graduate School of Arts and Sciences and Harvard-MIT Division of Health Sciences and Technology, describes a way to engineer the evolutionary landscape that viruses experience, pushing them away from dangerous variants and into evolutionary dead ends.

AstraZeneca is advancing cell therapy research to expand treatment possibilities beyond current applications in blood cancers to solid tumors and autoimmune diseases. The company is developing three distinct platforms: autologous therapies that isolate and engineer a patient's own T cells to target disease; allogeneic off-the-shelf therapies created from donor T cells for immediate availability to multiple patients; and in vivo therapies using viral vectors to reprogram T cells directly within the body. These approaches include CAR-T cells engineered to recognize surface proteins on disease cells and TCR-T cells designed to target intracellular cancer-specific mutations. AstraZeneca's strategy focuses on harnessing the immune system's natural defenses by engineering T cells to precisely attack cancer cells and reset immune-mediated disease drivers. By investing in state-of-the-art platforms and building global capabilities, the company aims to democratize cell therapy access worldwide, removing barriers that currently limit patient benefit and unlocking the full curative potential of this innovative modality across multiple therapeutic areas.

Cancer immunotherapy has revolutionized oncology by shifting treatment focus from targeting tumor cells to modulating patient immune responses. Immune checkpoint inhibitors blocking pathways like PD-1/PD-L1 and CTLA-4 have pioneered this approach, alongside diverse strategies including monoclonal antibodies such as trastuzumab and cetuximab, bispecific antibodies like blinatumomab and teclistamab, antibody-drug conjugates including brentuximab vedotin and trastuzumab emtansine, CAR-T and CAR-NK engineered cells, mRNA vaccines, and emerging technologies like oncolytic viruses and exosomes targeting the tumor microenvironment. Despite these advances making immunotherapy a cornerstone of modern cancer treatment, significant clinical challenges limit widespread adoption. Response rates vary considerably, ranging from twenty to forty percent with checkpoint inhibitors to fifty to ninety percent with CAR-T cells and seventy-three percent with CAR-NK cells. Additionally, patients face primary resistance, secondary resistance following initial response, and hyper-progressive disease occurring in ten to thirty percent of cases. Identifying predictive biomarkers for immunotherapy response is critical for overcoming treatment resistance, minimizing immune-related adverse events, and enabling personalized treatment strategies that optimize outcomes while reducing unnecessary exposure to ineffective therapies.

Despite significant therapeutic advances including CDK4/6 inhibitors and antibody-drug conjugates for hormone receptor-positive, HER2-low metastatic breast cancer, real-world treatment patterns reveal persistent clinical challenges. A retrospective analysis of 2,662 patients with metastatic HR-positive, HER2-low disease from the Flatiron Health Research Database (diagnosed 2018-2023) examined treatment patterns across five lines of therapy. First-line treatment remained predictable, with 86.2% receiving endocrine therapy-containing regimens, predominantly ET plus CDK4/6 inhibitors (57.1%), while adoption of CDK4/6 inhibition increased from 51.9% to 60.7% between 2017-2023. However, critical findings emerged after progression: endocrine-containing regimens progressively declined from 86.2% in the first line to 50.3% by the fifth line, reflecting progressive endocrine resistance. This pattern illustrates a fundamental problem in metastatic breast cancer management—as endocrine options become exhausted through repeated exposure, treatment becomes increasingly heterogeneous, chemotherapy use rises, and disease control shortens dramatically. These findings underscore the urgent clinical need for alternative therapeutic strategies beyond traditional endocrine approaches in this patient population.